High Apolipoprotein B/Apolipoprotein A1 is Associated with Vitamin D Deficiency Among Type 2 Diabetes Patients
DOI: https://doi.org/10.2147/dmso.s465391
2024-06-11
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Shuqi Wang, 1, 2 Haina Gao, 3 Mengmeng Zhang, 1, 2 Shuchun Chen 1, 2 1 Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People's Republic of China; 2 Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's Republic of China; 3 Department of Internal Medicine, The Second Hospital of Shijiazhuang, Shijiazhuang, People's Republic of China Correspondence: Shuchun Chen, Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's Republic of China, Tel/Fax +86 31185988406, Email Purpose: To explore the relationship between vitamin D (VitD) deficiency and the apolipoprotein B/apolipoprotein A1 (apo B/A1) in type 2 diabetes mellitus (T2DM) patients. Methods: This was a retrospective study that lasted 2 years and 6 months, collecting information and laboratory data from 784 patients with T2DM. Patients were divided into VitD deficiency group (n = 433) and non-VitD deficiency group (n = 351) based on VitD levels. Calculated apo B/A1 ratio, and patients were further divided into high-apo B/A1 group (n = 392) and low-apo B/A1 group (n = 392) based on the median of the apo B/A1. All data were analyzed using Prism 8.0.1 and R version 4.3.1 software. Results: Apo B/A1 levels of T2DM patients combined with VitD deficiency was significantly higher than that of non-VitD deficiency patients, and the VitD levels of patients with high apo B/A1 was significantly lower than that patients with low apo B/A1 (all P< 0.001). Spearman correlation analysis showed that VitD levels were negatively correlated with apo B/A1 (r=-0.238, P< 0.001). Multiple linear regression analysis revealed after adjusting other factors, VitD levels were significantly negatively associated with apo B/A1 (β=-0.123, P=0.001). Binary logistic regression analysis showed apoB/A1 was an independent risk factor for VitD deficiency in T2DM patients. Restrictive cubic spline indicated a significant linear relationship between apoB/A1 and VitD deficiency (P general trend < 0.0001, P nonlinear = 0.0896), after stratification of gender, the results showed that apo B/A1 was more susceptible to VitD deficiency in female patients. The receiver operating characteristic (ROC) curve analysis showed that the area under the curve, sensitivity and specificity of the apo B/A1 for VitD deficiency were 0.654, 66.3% and 59.8%, respectively. Conclusion: The apo B/A1 was significantly negatively associated with VitD levels and an independent risk factor for VitD deficiency in patients with T2DM. Keywords: type 2 diabetes mellitus, vitamin D deficiency, apolipoprotein B/apolipoprotein A1 Due to population aging, obesity, lack of exercise and other factors, the global incidence of diabetes has increased rapidly and is expected to increase to 629 million by 2040. Among them, the vast majority of diabetics show type 2 diabetes mellitus (T2DM). 1 T2DM seriously damages the physical and mental health of patients and poses huge challenges to global healthcare systems. Studies have shown that the cost of T2DM treatment and care is 3.2 times higher than the average per capita healthcare expenditure, increasing to 6.4 times in the presence of cardiovascular disease (CVD) complications. 2 Therefore, identifying more treatment targets for T2DM is particularly important for patient prognosis. Recently, numerous studies have extensively explored the relationship between vitamin D (VitD) levels and islet beta cell function in T2DM patients, reporting a strong correlation between the two variables. 3–5 A recent meta-analysis summarizing three clinical randomized trials found that VitD reduced the risk of T2DM in patients with prediabetes by 15% (risk ratio: 0.85; 95% confidence interval (CI): 0.75–0.96), with an absolute risk reduction of 3.3% within 3 years (95% CI: 0.6–6.0%). 5 In addition, low VitD levels in T2DM patients are often accompanied by a higher incidence of CVD in diabetes. 6,7 A prospective study by Wan et al pointed out that compared with VitD deficiency, the CVD risk ratio in T2DM patients without VitD deficiency was 0.75 (95% CI: 0.64, 0.88). 7 Thus, maintaining sufficient levels of VitD in T2DM patients is of great significance in preventing the occurrence of CVD. Dyslipidemia in patients with T2DM is an important risk factor for diabetic CVD, especially low-density lipoprotein cholesterol (LDL-C) in blood lipids. When the vascular endothelium is damaged, foam cells engulf the oxidized LDL-C to form lipid stripes, which is the main pathological basis of atherosclerosis. 8 In recent years, the apolipoprotein family has gradually attracted substantial attention -Abstract Truncated-
endocrinology & metabolism